- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Cryoport Inc(CYRX)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for CYRX
11/13/2026: CYRX (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Cryoport Inc is a specialized life sciences tools and services company providing integrated temperature-controlled supply chain solutions, biostorage, and cryogenic equipment primarily for cell and gene therapies. The company's main business strengths include its proprietary Cryoportal tracking platform, a global service network, and market leadership in cryogenic storage systems through MVE. Its primary growth opportunity lies in supporting the expanding commercial pipeline of regenerative medicine treatments. However, execution risks remain around achieving sustained profitability and navigating fluctuating biotech funding cycles. The stock suits growth investors willing to tolerate volatility while monitoring clinical trial progress and operating margin improvements.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | Cryoport offers direct exposure to the high-growth secular tailwinds of commercial cell and gene therapy pipelines. |
| Momentum investor | Strong fit while signal remains positive | The stock frequently reacts positively to clinical trial expansion milestones and upward revenue guidance revisions when market momentum is favorable. |
| Value investor | Weak fit | The company is currently prioritizing operational scale over near-term bottom-line earnings and positive net income. |
| Dividend investor | Weak fit | Cryoport does not pay dividends, retaining all cash flows to fund internal development and expansion. |
| Low-risk investor | Weak fit | High share price volatility and exposure to early-stage biotechnology financing cycles introduce elevated risk. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock experiences notable price swings driven by macro biotech funding sentiment and quarterly clinical milestone updates. |
| Valuation risk | Medium / high | Valuation multiples depend heavily on long-term growth assumptions for the regenerative medicine sector. |
| Competition risk (specialized cold-chain and life sciences tools providers) | Medium | Larger life sciences tools enterprises could expand into integrated cryologistics, increasing pricing pressure. |
| Business quality | Medium / high | Cryoport maintains a defensible niche with specialized infrastructure, though profitability is still scaling. |
| Dividend income | Low / none | Income-focused investors receive zero dividend yield as capital is reinvested into the business. |
| Execution risk | Medium / high | Successfully scaling global supply chain operations and integrating past acquisitions is critical to achieving sustained profitability. |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.01B USD | Price to earnings Ratio - | 1Y Target Price 22.33 |
Price to earnings Ratio - | 1Y Target Price 22.33 | ||
Volume (30-day avg) 1.1M shares | Beta 1.87 | 52 Weeks Range 7.61 - 21.78 | Updated Date 11/15/2026 |
52 Weeks Range 7.61 - 21.78 | Updated Date 11/15/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.9 |
Sector & Industry Intelligence
Sector
Industrials
Constructive- Sentiment
- Bullish
- Momentum
- BUY Breadth Improving
- BUY participation
- 39.5%
- Active BUY / eligible
- 30 / 76
- 30-Day BUY Count Change
- +12
- Market state
- Bullish
More qualifying stocks are receiving or maintaining BUY advisories, indicating improving market participation.
Industry
Integrated Freight & Logistics
- BUY participation
- 0.0%
- Active BUY / eligible
- 0 / 2
- 30-Day BUY Count Change
- 0
Eligible universe: 2 stocks.
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.

Moderately Choppy
The stock has experienced noticeable price swings while retaining some directional structure.
Analysis of Past Performance
Type Stock | Historic Profit -25.62% | Avg. Invested days 28 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Life Sciences Services | Revenues from specialized BioLogistics shipping, chain-of-identity tracking via the Cryoportal, and biostorage/bioservices. | This is the core service engine that generates recurring revenue each time a clinical trial or commercial therapy is transported. |
| Life Sciences Products | Sales of MVE cryogenic freezers, dewars, and temperature-monitoring hardware to research labs and biopharma clients. | Provides equipment sales that complement logistics services and capture upfront capital spending in life science facilities. |
| Geographic Exposure (Americas, EMEA, APAC) | Global distribution spanning major life science hubs across North America, Europe, the Middle East, Africa, and Asia-Pacific. | Offers diversified international exposure to global biopharmaceutical R&D and clinical trial activity. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE - | Forward PE 76.34 | Enterprise Value 894.12M | Price to Sales(TTM) 5.24 |
Enterprise Value 894.12M | Price to Sales(TTM) 5.24 | ||
Enterprise Value to Revenue 4.65 | Enterprise Value to EBITDA -13 | Shares Outstanding 50.65M | Shares Floating 46.01M |
Shares Outstanding 50.65M | Shares Floating 46.01M | ||
Percent Insiders 4.74 | Percent Institutions 92.57 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

